{"result": "(\"entity\"<|>GOTTSCHLICH<|>PERSON<|>Gottschlich is an author of a study involving 50 patients with burn injuries, focusing on the effects of an immunomodulatory diet.)\n##\n(\"entity\"<|>SAFFLE<|>PERSON<|>Saffle is an author who compared an immunomodulatory formula against an enriched formula without arginine in burn patients.)\n##\n(\"entity\"<|>BROWN<|>PERSON<|>Brown is an author of a study that found differences favoring an immunomodulatory formula in infection rates among trauma patients.)\n##\n(\"entity\"<|>KUDSK<|>PERSON<|>Kudsk is an author of a study that reported lower infection rates in trauma patients using an immunomodulatory formula.)\n##\n(\"entity\"<|>ALITRAQ<|>ORGANIZATION<|>Alitraq is a nutritional formula with specific compositions aimed at providing immunonutrients for patients.)\n##\n(\"entity\"<|>IMPACT ENTERAL<|>ORGANIZATION<|>Impact Enteral is a nutritional formula designed for enteral feeding, containing specific macronutrient ratios.)\n##\n(\"entity\"<|>IMPACT ORAL<|>ORGANIZATION<|>Impact Oral is a nutritional formula intended for oral consumption, providing essential nutrients for recovery.)\n##\n(\"entity\"<|>PATIENTS CONCERNING BURNS<|>EVENT<|>The event refers to the clinical studies conducted on patients with burn injuries to assess the effectiveness of immunomodulatory diets.)\n##\n(\"entity\"<|>PATIENTS WITH TRAUMATIC INJURIES<|>EVENT<|>The event refers to clinical studies involving patients with traumatic injuries to evaluate the impact of immunonutrition.)\n##\n(\"relationship\"<|>GOTTSCHLICH<|>PATIENTS CONCERNING BURNS<|>Gottschlich conducted a study involving burn patients to assess the effects of an immunomodulatory diet<|>8)\n##\n(\"relationship\"<|>SAFFLE<|>PATIENTS CONCERNING BURNS<|>Saffle compared different nutritional formulas in a study involving burn patients<|>7)\n##\n(\"relationship\"<|>BROWN<|>PATIENTS WITH TRAUMATIC INJURIES<|>Brown's study focused on the effects of immunomodulatory formulas on infection rates in trauma patients<|>8)\n##\n(\"relationship\"<|>KUDSK<|>PATIENTS WITH TRAUMATIC INJURIES<|>Kudsk's research evaluated the impact of immunonutrition on infection rates in trauma patients<|>8)\n##\n(\"relationship\"<|>ALITRAQ<|>PATIENTS CONCERNING BURNS<|>Alitraq is a nutritional formula used in studies involving burn patients<|>6)\n##\n(\"relationship\"<|>IMPACT ENTERAL<|>PATIENTS WITH TRAUMATIC INJURIES<|>Impact Enteral is a formula that may be used in the nutritional support of trauma patients<|>6)\n##\n(\"relationship\"<|>IMPACT ORAL<|>PATIENTS CONCERNING BURNS<|>Impact Oral is a formula that could be utilized in the dietary management of burn patients<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: icos de la administración de este aminoácido es su papel como precursor del óxido nítrico, pudiendo estar relacionado con la mortalidad en pacientes hemodinámicamente inestables como los que presentan un shock séptico⁷.\n\n## 3. Implicaciones clínicas de fórmulas inmunomoduladoras\n\nUno de los grandes problemas metodológicos de los estudios de investigación realizados en el área de la inmunonutrición es la utilización de fórmulas con múltiples inmunonutrientes, siendo imposible comparar el efecto aislado de cada uno de ellos, encontrando por tanto el efecto de un «cocktail» de inmunonutrientes sobre variables clínicas y bioquímicas. Las fórmulas enterales y suplementos comercializados que podemos considerar como inmunomoduladoras son múltiples, a modo de resumen las ex-\n\n## 3.1. Pacientes quemados\n\nUno de los primeros estudios realizados fue el de Gottschlich et al⁸, con 50 pacientes y un 40% de superficie corporal quemada. Este autor divide a los pacientes en tres grupos: un grupo con dieta inmunomoduladora: 17 pacientes con una fórmula con un 9% de arginina y un 50% de grasas de pescado; y dos grupos con fórmula estándar. En este trabajo se detectó una disminución significativa de infecciones de la herida (inmunonutrición 11% frente a 57% y 42% de las dos fórmulas estándar). Como resultados secundarios, observa menor incidencia de diarrea y mejor control glucémico, con menor estancia hospitalaria por porcentaje de quemadura en el grupo de fórmula modular inmunomoduladora. Posteriormente, Saffle et al.⁹ compararon una fórmula inmunomoduladora frente a una enriquecida pero sin arginina. En este trabajo no se encontraron diferencias significativas en ninguna de las variables analizadas. Otro ensayo aleatorizado¹⁰ en pacientes quemados ha mostrado cómo la suplementación diaria con 40,4 umol de cobre, 2,9 umol de selenio y 406 umol de zinc durante 30 días reducía el número de bronconeumonías y la estancia hospitalaria. En otro ensayo clínico aleatorizado¹¹, se evaluaron 36 pacientes (16 con traumatismos y 20 quemados). La estancia en la UCI fue inferior con la fórmula inmunomoduladora (3,41 frente a 7,83 días), así como la necesidad de días con soporte respiratorio (2,71 y 7,39 días). Por último, en una reciente revisión Cochrane¹², se evaluaron 16 estudios con 678 pacientes, mostrando cómo el uso de glutamina comparado con una forma isonitrogenada reduce la estancia hospitalaria (–5,65 días, 95% [CI] –8,09 a –3,22) y la mortalidad ([RR] 0,25, 95% CI 0,08 to 0,78).\n\n## 3.2. Pacientes críticos de origen traumatológico\n\nEl primer trabajo fue realizado por Brown et al.¹³, en este estudio se encuentran diferencias a favor de la fórmula inmunomoduladora (16% frente a 56%) en la tasa de infecciones, con una alta incidencia de neumonía en ambos grupos (53% frente a 83%). Otro trabajo en este grupo de pacientes es el realizado por Kudsk et al.¹⁴ con 70 pacientes en total. Este trabajo presenta una menor tasa de infecciones en general (31% frente a 65%), a expensas de la disminución de abscesos intraabdominales (6% frente a 35%), por lo que observan menor consumo de antibióticos, menor estancia\n---\n## BLOQUE: SOPORTE NUTRICIONAL AVANZADO\n\n### Tabla 2. Composición de las fórmulas enterales con inmunonutrientes.\n\n| Nombre | Kcal/cc | Proteínas (g/100 cc) | Grasas (g/100 cc) | Carbohidratos (g/100 cc) | Osmolaridad (mOs/l) | ω-3 (g/100 cc) ratio ω-6/ω-3 | Arginina (g/100 cc) | Glutamina (g/100 cc) |\n|---------|---------|----------------------|-------------------|--------------------------|---------------------|------------------------------|---------------------|----------------------|\n| Alitraq | 1 | 5,3 42% péptido | 1,5 53% MCT | 16,4 | 480 | 0,15 4,23 | 0,45 | 1,42 |\n| Impact enteral | 1 | 5,6 | 2,8 27% MCT | 13,4 | 477-519 | 0,34 0,7 | 1,25 | - |\n| Impact oral | 1 | 7\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}